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Abstract
Chronic Beryllium (Be) Disease (CBD) is a granulomatous disorder that predominantly affects the lung. The CBD is caused by
Be exposure of individuals carrying the HLA-DP2 protein of the major histocompatibility complex class II (MHCII). While the
involvement of Be in the development of CBD is obvious and the binding site and the sequence of Be and peptide binding
were recently experimentally revealed [1], the interplay between induced conformational changes and the changes of the
peptide binding affinity in presence of Be were not investigated. Here we carry out in silico modeling and predict the Be
binding to be within the acidic pocket (Glu26, Glu68 and Glu69) present on the HLA-DP2 protein in accordance with the
experimental work [1]. In addition, the modeling indicates that the Be ion binds to the HLA-DP2 before the corresponding
peptide is able to bind to it. Further analysis of the MD generated trajectories reveals that in the presence of the Be ion in
the binding pocket of HLA-DP2, all the different types of peptides induce very similar conformational changes, but their
binding affinities are quite different. Since these conformational changes are distinctly different from the changes caused by
peptides normally found in the cell in the absence of Be, it can be speculated that CBD can be caused by any peptide in
presence of Be ion. However, the affinities of peptides for Be loaded HLA-DP2 were found to depend of their amino acid
composition and the peptides carrying acidic group at positions 4 and 7 are among the strongest binders. Thus, it is
proposed that CBD is caused by the exposure of Be of an individual carrying the HLA-DP2*0201 allele and that the binding
of Be to HLA-DP2 protein alters the conformational and ionization properties of HLA-DP2 such that the binding of a peptide
triggers a wrong signaling cascade.
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Introduction
Chronic Beryllium Disease (CBD) is a pulmonary granuloma-
tous disorder caused by an immune reaction when individuals are
exposed to beryllium (Be) [2]. About 18% of people who are
exposed to Be in the workplace may develop CBD depending on a
number of risk factors such as their genetic susceptibility, the
duration, the concentration of the Be exposure, and their smoking
habits [3,4,5,6,7]. Out of these risk factors, the genetic suscepti-
bility of the individuals is shown to be the dominant contributor in
the development of CBD [2,8,9]. Understanding the molecular
mechanism of CBD would help prevention and treatment of
disease [10,11,12,13,14].
The Major Histocompatibility Complex II (MHC II) controls
the activation of the immune system in response to foreign
microorganisms. The first component in this process is the binding
of small peptides (that are part of an antigen) to the MHC II. The
second component is the conformational change of MHC II
induced by the peptide binding which makes the MHC II complex
‘‘recognizable’’ by T-cell receptors along with the subsequent
activation of T-cells (TCs) [9,15,16]. Different conformational
changes result in the activation of different TCs and thus lead to
different immune responses. These conformational changes are
caused by the binding of variety of peptides to alleles of MHC II.
In addition, the associations of MHC II alleles with various
diseases have been previously reported [17,18,19].
Of particular interest for this study is one of the MHCII
molecules, the HLA-DP2 (coded by DPA1*0103, DPB1*0201),
which has been shown to be associated with development of CBD
[3,20,21]. By analyzing various HLA-DP molecules of the MHCII
and focusing on the amino acid sequence forming the peptide
binding pocket, it was demonstrated that approximately 85% of
CBD patients have a glutamic acid residue at position 69 in the b-
chain (bGlu69) of HLA-DP [20,22]. In other HLA-DP proteins,
position 69 is taken by a lysine (Lys) amino acid. Because the side
chain of Glu residue is shorter than of Lys, it can be speculated
that the binding pocket of HLA-DP2 is wider comparing with the
other HLA-DP.
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The selectivity of HLA-DP2 towards different peptides is
typically analyzed by reviewing the corresponding binding pockets
for each amino acid of the peptide. Typically these pockets are
labeled according to the residues in the peptide, i.e. pocket p1
refers to the protein pocket where the side chain of the first amino
acid of peptide will be accommodated. Some of these pockets are
very specific, others are not. Thus, the crystal structure of HLA-
DP2 with a self-peptide derived from the HLA-DR a-chain
(pDRA) [23] reveals that HLA-DP2 has four pockets which are
able to bind variety of amino acids [4,23,24,25]. Thus, the p1
pocket prefers hydrophilic residues, p2 can accommodate posi-
tively charged residues, p6 could be occupied with aromatic
residues, and p9 might accept larger residues. A molecular docking
approach discovered that p1, p2 and p6 peptide positions are the
most important for binding to the HLA-DP2 protein [24,26].
Comparing HLA-DP molecules with the HLA-DP2, the replace-
ment of Lys69 with Glu69 (pointing toward peptide position 7, p7)
and the other two glutamic acid residues, bGlu68 and bGlu26
(pointing toward p4 and p6), on HLA-DP2, results in an acidic
pocket that might potentially accommodate the Be ion [1,23,26].
The existence of such an acidic pocket, providing a strong negative
potential, was the reason for the speculation that even an
endogenous self-peptide with Be can bind to HLA-DP2 and be
recognized by the T cells [26]. Thus a recent ex vivo study
demonstrated that some endogenous self-peptides are able to bind
with HLA-DP2 in the presence of Be [26]. When these peptides
were exposed to the HLA-DP2 protein, Be-responsive TC
receptors were able to recognize those peptides and stimulate
the accumulation of cytokines by TCs. Another study examined 40
human peptides for their ability to stimulate the secretion of
interleukin-2 (IL-2), a type of cytokine signaling molecule secreted
mainly by CD4+ and CD8+ T-cell, ex vivo, and 11 of them were
found to initiate production of IL-2 by TCs in the presence of the
Be ion [26].
Although, in multiple papers the Be ion is suggested to bind
directly to HLA-DP2 [27,28], only recently it was experimentally
shown [1] that Be binds first and then the peptide binds to the
HLA-DR2-Be complex. However, the reason for this sequence of
events is not clear and here we provide plausible explanation based
on binding energy calculations. In addition, it is not clear if the
sequence of the binding events causes different conformational
changes of the HLA-DR2-Be-peptide complex. In this work, we
investigate in silico both scenarios: (a) peptides which bind to the
protein with the Be ion placed inside the protein pocket which
induces conformational changes in HLA-DP2 that are necessary
for its recognition by TCs; and (b) the Be ion binds to the peptide
first and thus changes the peptide-binding specificity and affinity to
HLA-DP2 resulting in conformational changes in the HLA-DP2
that are necessary for its recognition by TCs. This is done by
analyzing the changes in binding affinity and conformational
changes of the protein upon binding the four sets of small peptides
(Figure 1): peptides that are known to cause the activation of TC
receptors in normal immune response; peptides that prefer to bind
Figure 1. Graphical depiction of our investigation of the effects
of the Be ion on the complex made up of a HLA-DP2 protein,
the Be ion, and a small peptide.We investigated four types of small
peptides (‘‘Natural’’, ‘‘Strong’’, ‘‘Weak’’, and ‘‘DR’’) and two binding
scenarios: (1) the ion bound to a small peptide and (2) the ion bound to
the HLA-DP2 protein. Effect predictions include binding affinity,
conformation changes of the peptide binding pocket, pKa shifts of
titratable groups of the protein upon peptide and/or the Be ion
binding.
doi:10.1371/journal.pone.0111604.g001
Figure 2. Illustration of the two investigated binding scenarios.
In the top panel (A) the Be ion is in complex with the protein and then
the peptides were added, peptideR(Be+protein) scenario; and in the
bottom panel (B) the Be ion is in complex with the peptides and then
the protein is added, (Be+peptide)Rprotein scenario.
doi:10.1371/journal.pone.0111604.g002
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to HLA-DR but not HLA-DP; and peptides that are known to
bind to the protein in the presence of the Be ion and induce the
production of high/low concentration of inflammation cytokines
in TCs that are the cause of the autoimmune disease [26]. It is
anticipated that by comparing the effects of each set of peptides we
will be able to reveal additional details of molecular mechanism of
CBD along the finding of recent experimental work [1].
Methods
This section describes the selection of peptides to be investigated
and the methods for the 3D structure modeling, the Be ion binding
site prediction, the molecular dynamics (MD) simulations, the
geometry analysis, the binding free energy and pKa calculations.
In each of the cases, two scenarios will be investigated: (a) the
peptide binding to the (Be-HLA-DP2) complex and (b) the Be
bound first to the peptide resulting in a (Be-peptide) complex, then
the Be-peptide complex binds to the HLA-DP2 protein (see
Figure 2, panels A and B respectively).
Selection of peptides to be investigated
To investigate the specificity of peptides to HLA-DP2, four
different classes of peptides were selected (Figure 1): (1) 10 peptides
that bind to the HLA-DP2 were selected from the 40 human
peptides based on their ability to stimulate the immune response
detected experimentally as an increase of the IL-2 secretion by
more than 15 pg/ml in the Be-specific T cell hybridomas AV22
and by 45 pg/ml in the Be-specific T cell hybridomas AV9, which
were termed ‘‘strong’’ peptides [26]; (2) 10 additional peptides
were selected from the same 40 human peptides which were also
found to increase the IL-2 secretion but not as much as the
peptides in the ‘‘strong’’ class (the increase of the IL-2 secretion
was less than 6 pg/ml in both Be-specific T cell hybridomas AV22
and AV9); these were termed ‘‘weak’’ peptides; (3) 10 peptides
which were bound to HLA-DP2 and known to trigger the immune
system reaction without the Be ion were chosen and were termed
‘‘natural’’ peptides [5]; and (4) 10 peptides that naturally bind to
HLA-DR which were randomly selected from syfpeithi database
(http://www.syfpeithi.de) and were termed ‘‘DR’’ peptides. This
last class was created because the HLA-DR structure is similar to
the HLA-DP2 structure [6], which provides the opportunity to
compare the physical properties of peptides binding to HLA-DR
and HLA-DP2. All peptides in each class were cut to a length of 10
amino acids. In investigating the molecular mechanism of CBD, it
is anticipated that peptides belonging to different classes may have
a different affinity and may induce different conformational
changes. For example, peptides from the ‘‘strong’’ class may have
the highest affinity to bind to HLA-DP2 in the presence of Be and
induce conformational and pKa changes distinctly different from
peptides in the ‘‘natural’’ and ‘‘DR’’ classes. The binding of
peptides in the ‘‘weak’’ class may cause effects similar to the
‘‘strong’’ peptides, but the magnitude of these changes is expected
to be smaller. Alternatively, it can be envisioned that the presence
of the Be ion in combination with the HLA-DP2 molecule is the
leading factor and any peptide will cause CBD.
Structure modeling
All of the above selected peptides are of various lengths which
could introduce artifacts into the computational modeling. So, this
is why the lengths need to be made the same. Since the
experimentally studied peptides (the ‘‘strong’’ and ‘‘weak’’ classes)
are of length 10 [23,26], the other ‘‘natural’’ and ‘‘DR’’ peptides
were also trimmed to a 10 amino acid length. The trimming was
guided by preserving the interactions of peptide residues with the
key amino acids in the HLA-DP2 protein [9,23,26].
The crystal structure of HLA-DP2 was retrieved from the
Protein Data Bank (PDB) (http://www.rcsb.org), PDB ID: 3LQZ.
It contains an a chain, a b chain, two ligand chemical
components, and it shows HLA-DP2 crystalized with a bound
natural peptide of 15 amino acids. We chose to include the 10
residues of the crystallized peptide that were located completely
within peptide binding pocket of HLA-DP2 (shown in red in
Figure 2): peptide residue numbers 1-10 (sequence
FHYLPFLPST), to be consistent with Ref. [1]. Our decision of
where to cut the peptide was reinforced based on the interaction of
the peptide with the key residues in the protein. We predict that
the positively charged Be ion will bind to the protein near the
negatively charged pocket formed by the three glutamic acid
residues in the protein (shown in green in Figure 2) at positions 68,
69, and 26 [20,23,26], in accordance with recent experimental
work [1]. Using the crystallographic structure, it was found that
the peptide residue numbers 4 and 7 are in close proximity to the
putative Be binding site and because of this, these two residues are
considered to be the key positions in the peptide. When choosing
where to cut the other ‘‘natural’’ and ‘‘DR’’ peptides, several
considerations were made. First, we wanted to keep the key
peptide positions, p4 and p7, and secondly we wanted to keep the
peptide residue number 10 as well. The reason for keeping peptide
residue number p10 is the following. In the HLA-DP2 protein
there is another key residue, an aspartic acid, at position 55 (also
shown in green in Figure 2) that is expected to form hydrogen
bonds with the peptides or the T-cell receptor. In the crystallized
natural peptide, possible interactions between the peptide and this
aspartic acid corresponds to a polar tyrosine at peptide amino acid
p10, making this position also a key residue in the peptide. Thus,
the final selection was made to consider the peptide segment from
residues 1-10 as a common 10 amino acid length segment for the
modeling of all the peptides.
The 3D structures of the ‘‘strong’’, ‘‘weak’’, and other ‘‘natural’’
peptides are not available in neither free form nor bound to HLA-
DP2 and therefore have to be modeled (note that the structure of
HLA-DP2-Be-peptide complex [1] was not available prior the
manuscript was submitted for review). We used the peptide in
PDB ID: 3LQZ as a template and have built models for the rest of
‘‘natural’’, ‘‘strong’’, and ‘‘weak’’ peptides bound to HLA-DP2. In
doing so, several considerations were made (all alignments are
available in Material S1). The alignment of the other natural
peptides to the 10 amino acid positions of the crystallized peptide
template were based mainly on maintaining the biophysical
characteristics of key peptide positions 4, 7, and 10. Additionally,
we also tried to maintain the biophysical properties of the
remaining 7 positions. For example, at positions 1 and 6 in the
crystallized peptide, there are hydrophobic phenylalanine residues.
Thus, in other peptides, we tried to conserve the biophysical
characteristics of these positions by aligning the other peptides to
have hydrophobic residues at positions 1 and 6. Similar
considerations were made for the alignment of the ‘‘strong’’ and
‘‘weak’’ peptides to the template peptide.
The alignment and cutting of the peptides that bind to HLA-
DR (‘‘DR’’ peptides) was done in a similar fashion. We started
with the crystallized structure of HLA-DR with a bound peptide
(PDB ID:1KG0). We then used the crystallized DR peptide as a
template for aligning and cutting other ‘‘DR’’ peptides. Because
we intended to use these peptides as a control (they do not
normally bind to HLA-DP2), we first aligned the peptide
crystallized with DR to the same peptide template used for the
‘‘natural’’ peptides (taken from PDB ID: 3LQZ) to increase the
Chronic Beryllium Disease
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likelihood of a peptide that naturally bind to HLA-DR to bind to
HLA-DP2. We did the alignment in the same way (aligning
residue positions 4, 7, 10, and then other positions) and cut the
crystallized HLA-DR peptide to include the amino acids 1-10
(sequence YVKQNTLKLA). (The fact that the DR-peptide was
also cut to include positions 1-10 was coincidental; the alignment
was based entirely on biophysical characteristics). After the ‘‘DR’’
peptide was aligned to and cut based on the HLA-DP2 peptide, we
then used it as a template for cutting the other 10 ‘‘DR’’ peptides.
The alignment was done in the same fashion as stated before for
the HLA-DP2 natural peptides. To create the three-dimensional
structures of the peptides, we used the crystallized peptide as a
structural template and mutated each residue individually via side
chain replacement using VMD [29]. Once all of the peptide
structure files were created, we then created additional structure
files containing the ion, protein, and peptide to represent the two
different binding processes. For the binding processes, we first
identified the appropriate binding site of the Be ion on both the
HLA-DP2 protein and the peptides.
Placement of the Be ion on the surface of HLA-DP2 and
the peptides
To investigate the sequence of forming the (Be-HLA-DP2-
peptide) complex, we modeled two different scenarios (Fig 3). This
is done for computational purposes to compare the energy
components and conformational changes, while not addressing
questions if this occurs intracellularly or on the cell surface.
(a) the Be ion is first bound to the HLA-DP2 protein forming a
(Be-HLA-DP2) complex, and then the peptides bind to the
(Be-HLA-DP2) complex (in text described as ‘‘peptideR(Be+
protein)’’ scenario); This requires predicting the Be binding
site on HLA-DP2 in the absence of the peptides.
(b) the Be is first bound to the peptide forming a (Be-peptide)
complex, that binds to the HLA-DP2 protein (in text
described as ‘‘(Be+peptide)RHLA-DP2’’ scenario). This
requires predicting the Be binding site on the free peptides.
It can be expected that the Be ion binds to the HLA-DP2 or to
the peptide surface non-specifically, and that the electrostatic force
favors this binding. To determine the position of the positively
charged Be ion on both the surface of the HLA-DP2 protein and
on the exterior of the small peptides that bind to the HLA-DP2
protein, we utilized the BION webserver (http://compbio.
clemson.edu/bion_server/) [30]. The algorithm implemented in
BION relies on a DelPhi [31] generated potential map in
conjunction with an in-house clustering algorithm [32]. The
predictions take into account the magnitude of the electrostatic
potential at selected surface-bound grid points and the biophysical
properties of the ions such as radius and charge. The represen-
tative grid points are sorted in descending order (by absolute value)
of the potential and the position of a given point within this list is
termed Rank. Only the first ranked plausible ion position was used
for further analysis. Note that Be ion binding sites for each
unbound peptide were independently predicted and are slightly
different depending on peptide sequence and conformation.
Placement of peptides onto the protein
Once the Be was placed onto either the protein or the peptide,
we then placed each of the 40 peptides separately into the HLA-
DP2 protein using Chimera [33]. Each peptide was placed in such
a way as to be as similar as possible to the placement of the natural
peptide found in the PDB file. We used the coordinates of the
crystallized HLA-DP2 peptide found in the PDB file as the initial
position of all the other peptides (‘‘natural’’, ‘‘strong’’, ‘‘weak’’, and
‘‘DR’’) when binding them to the HLA-DP2 protein. When there
were clashes between the side chains of the peptide and the side
chains of the HLA-DP2, we manually adjusted the position of the
entire peptide in order to very slightly lift the peptide out of the
peptide binding pocket of HLA-DP2 or tilt the peptide within the
pocket until the side chains did not overlap. In the case where the
peptide side chains overlapped with the ion radius, side chain
rotamers defined in the Chimera rotamer library were used to
eliminate the overlap. All structures are available for download
from http://figshare.com/articles/Chronic_Beryllium_Disease_
Revealing_the_role_of_beryllium_ion_and_small_peptides_binding
_to_HLA_DP2/1147422.
Energy minimization and MD simulations
Once the structures were built, the protein, peptides and Be ion
were relaxed and simulated using NAMD [34]. Each case was split
by chain and protonated using the Charmm22 force field. These
protonated chains were then recombined and an explicit water
sphere was created around the complex using VMD with the
TIP3P water model [29]. This sphere was created with a padding
of 15 A˚ around the protein. To avoid initial structural clashes this
structure was first relaxed by NAMD software [34] for 5000 steps
via its conjugate gradient algorithm, and then, the minimized
structure was simulated at a temperature of 298K for 1
nanosecond using 2 femtosecond time steps. The simulation used
spherical boundary conditions to contain the complex and
Langevin dynamics to incorporate random forces and damping
of motion into the run. Every 100 steps, a snapshot of the protein
was exported to a DCD trajectory file that was later unzipped into
multiple PDB snapshots.
RMSD and pocket distance analysis
Once the results were obtained from the MD simulation, the
snapshots of each of the cases were utilized for the screening of
conformational changes of the Be binding pocket of the protein as
a function of time. These changes in HLA-DP2 pocket due to the
Figure 3. The HLA-DP2 binding pocket in complex with the
crystallized natural peptide of 15 residues. The 10 residues of the
peptide used as a cutting template are shown in red with important
residues having extended structure. The removed residues are in
yellow. Key residues in HLA-DP2 are shown in green; the aspartic acid is
labeled as ASP and the three glutamic acid residues are labeled as GLU
Pocket.
doi:10.1371/journal.pone.0111604.g003
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binding of small peptides and the Be ion were analyzed in two
ways:
1. The change in RMSD of residues 50–86 of chain B (Figure 4,
labeled in dark purple). Our preliminary data suggests that
among two helices (one formed by chain A residues, and
another by chain B residues) that form the peptide-binding
pocket of HLA-DP2, the helix that is formed by chain B
residues experiences the primary conformational transforma-
tion upon interacting with the ‘‘natural’’ peptides (not
presented).
2. In order to depict the process of the opening-closing of the
pocket, we observed the change in five different distances
between pairs of residues between the helices forming the
peptide-binding pocket of HLA-DP2 (Table 1, Figure 4,
labeled in red).
For statistical significance, we used the peptide class represen-
tative RMSD and the distances between five pairs of residues that
were calculated as the median RMSD values, and as the mean of
distance values respectively within each case in the group.
Binding energy calculations
The binding free energy of the energetically-minimized protein
complex was calculated via the following [35,36,37,38]:
DG~GAB{GA{GB ð1Þ
where GAB is the free energy of the complex; GA and GB are
energies of A and B parts of the complex. Only the electrostatic –
Coulombic (EE) and polar component of solvation energy (SP) –
were calculated using the Delphi software (scale was 1 A˚ per grid,
perfil 70%, dielectric constants for protein and water were 1 and
80 respectively) [31] and van der Waals (VE) energies, calculated
with NAMD [34] (we used the data from one step of the
minimization of complex and each of its partners), were taken into
account in order to calculate the free energy of the complex and
each of its parts:
G~EEzSPzVE ð2Þ
.
Such an approach, with slight variations, was previously applied
by us to model the changes of the binding free energy
[35,36,37,38] and a variation of this method was benchmarked
against experimental data [39]. For ‘‘(Be+peptide)Rprotein’’
scenario (Be ion bound first to the peptide), the binding energy
was calculated between the protein (GA) and the complex of the
peptide and the Be (GB). For the ‘‘peptideR(Be+protein)’’ scenario
(Be attached to the protein first), we analyzed the binding affinity
between the protein (GA) and the Be-peptide complex (GB). We
also calculated the binding free energy between peptides (GA) and
HLA-DP2 protein (GB) when modeled without the Be ion. In both
cases, GAB refers to the energy of the entire complex Be-HLA-
DP2-peptide. It should be pointed out that the current
implementation of eq. (2) does not use weighted coefficients and
thus overestimates the energy changes, as outlined in another
study of protein folding free energy [40]. Due to this, the results
obtained using eq. (1) are used for ranking only, not to infer
absolute binding free energy changes.
pKa calculations
We also performed pKa calculations for the ionizable groups
within these complex structures and investigated the effects of the
presence of the Be ion. The pKa values were obtained with Multi-
Conformer-Continuum-Electrostatics (MCCE) program [41,42,43].
MCCE calculates the equilibrium state of each conformation and
Figure 4. Cartoon representation of HLA-DP2 protein (PDB ID
3LQZ). Peptide binding pocket is shown in light and dark purple.
Residues taken into account for distance calculations are in red. Change
in RMSD due to peptide/Be binding was analyzed for residues in dark
purple. Illustration was made with Chimera software [33].
doi:10.1371/journal.pone.0111604.g004
Table 1. Selected distances between residues forming peptide-binding pocket of HLA-DP2.
Distance label Residue 1 Residue 2
1 Arg76.A Glu50.B
2 Leu70.A Tyr58.B
3 Ile65.A Asp64.B
4 Leu60.A Met76.B
5 Ala56.A Leu83.B
doi:10.1371/journal.pone.0111604.t001
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the charged state of the ionizable residues. It simulates the
conformational and ionization changes in a Monte Carlo procedure
and couples the protonation events with the conformational changes.
The calculation was done as a function of pH with an internal
dielectric constant of 4.0. The Be ion topology file was created with
the parameters: radius = 1.53 A˚, charge =+2.0e, and reference
energy =218.430 Kcal/mol.
The pKa calculations were performed on 40 bound complex
structures in absence of Be ion (protein+peptide) along with 80
structures with the Be ion (40 structures of the peptides bound to
the Be-HLA-DP2 complex and 40 structures of HLA-DP2 to bind
with the Be-peptide complex). MCCE predicted the pKa value of
the ionizable residue of each structure, and the pKa shifts were
analyzed and discussed, with emphasis on the role of the Be ion
and the binding.
Results and Discussion
At normal conditions, MHCII controls the activation of the
immune system in response to foreign microorganisms. Its proteins
bind a very specific range of exogenous peptides to the peptide-
binding pocket and undergo some conformational changes that
are recognizable by various TC receptors. However, in patients
with CBD, high concentration of Be ions was shown to influence
HLA-DP2 activity and resulting in the initiation of ‘‘false’’ signal
cascades that cause the development of the chronic autoimmune
disease. In order to investigate the molecular mechanism of the
HLA-DP2 malfunction in the presence of Be ions, we investigate
two scenarios: peptideR(Be+protein) and (Be+peptide)Rprotein,
along with the binding of four different sets of peptides (‘‘natural’’,
‘‘DR’’, ‘‘strong’’, and ‘‘weak’’, see Methods section for details).
The goal is to analyze the changes in the key processes of the initial
immune response associated with HLA-DP2 (peptide binding and
subsequent protein conformational changes) for all cases. It is
important to emphasize that the binding site of TC receptors is on
the same side of the peptide-binding pocket of HLA-DP2, and thus
the ‘‘false’’ signal cascade initiation depends mostly on the
conformational change of the protein, and the strength of peptides
binding to the protein might be less important for the process of
the complex recognition by TC receptors. As the manuscript was
under review, this hypothesis was experimentally confirmed and it
was shown that TC receptor recognizes the conformational
changes in the surface of DP2-peptide complex induced by the
internally bound Be ion [1].
Binding affinity of small peptides to HLA-DP2 protein
If the immune response is related to the binding affinity of the
corresponding peptides to HLA-DP2, then one can expect that the
peptides in the ‘‘strong’’ set should have the strongest affinity in the
presence of the Be ion, and this affinity should be similar to the
affinity of the ‘‘natural’’ set of peptides in the absence of the Be
ion. The Be ion should favor binding of peptides in the ‘‘weak’’ set
to the protein as well, however, the binding affinity should be
smaller than for peptides in the ‘‘strong’’ set. Furthermore one
expects the ‘‘DR’’ peptides to have the lowest or no affinity to
HLA-DP2, in both the presence and in the absence of the Be ion.
Although the binding affinity may not be a key factor, as indicated
above, the binding free energy estimations may address the
question of which scenario is more energetically favorable, the
scenario ‘‘peptideR(Be+protein)’’ or ‘‘(Be+peptide)Rprotein’’.
Figure 5 shows the calculated binding free energy (eq.1) after
5000 steps of minimization. The grouped box chart was created
based on the data for all of the peptides within the corresponding
set (‘‘strong’’, ‘‘weak’’, ‘‘natural’’, and ‘‘DR’’) and based on the
model for placing the Be ion in the complex (‘‘peptideR(Be+
protein)’’ and ‘‘(Be+peptide)Rprotein’’).
The immediate observation can be made by comparing
Figure 5.B and C: The scenario ‘‘(Be+peptide)Rprotein’’ is less
energetically favorable than the ‘‘peptideR(Be+protein)’’ scenario.
This is due to several reasons. The peptides themselves, including
‘‘strong’’ and ‘‘weak’’ peptides, do not have an acidic cluster, i.e.
do not have a binding pocket with a strong negative potential
which can attract positively charged Be ions. In addition, free
peptides are expected to be quite flexible and therefore are unable
to keep tightly bound ions.
Comparing Figure 5.A (binding without the Be ion) and
Figure 5.B (binding with the Be ion), no significant changes are
Figure 5. Binding free energy between A) peptides and HLA-DP2 protein without the Be ion; B) peptide and complex of HLA-DP
protein with the Be ion in case of peptideR(Be+protein) scenario; C) complex of peptides and the Be ion with the protein for
(Be+peptide)Rprotein scenario.
doi:10.1371/journal.pone.0111604.g005
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predicted for each of the peptides, however, ‘‘strong’’ peptides are
predicted to have the highest affinity. The reason for this
prediction will be discussed in the pKa section below. Here, we
simply mention that the formation of the acidic cluster of three
Glu residues affects the protonation states of these Glu residues in
both the free HLA-DP2 and in the bound HLA-DP2 protein.
These changes are not taken into account in the protocol that
calculates the binding free energy. This was done to study the
binding, conformational, and ionization changes separately.
Further analysis of Figure 5 reveals that the binding affinities
are ranked in accordance with our expectations: the peptides in
the ‘‘strong’’ set are the strongest binders, followed by ‘‘weak’’,
‘‘natural’’, and ‘‘DR’’ peptides. As we have indicated above, the
binding free energies are for ranking only and it is quite possible
that ‘‘DR’’ peptides do not bind at all to HLA-DP2.
Conformational changes in HLA-DP2 upon small
peptides and/or Be ion binding
The binding of the peptide and the Be ion to HLA-DP2 should
trigger conformational changes that are distinctly different from
the conformational changes induced by ‘‘natural’’ peptides in the
absence of Be. This is what will initiate the ‘‘false’’ signaling
cascade and is the cause of CBD. We assume that these
conformational changes should be caused by distinct different
conformational changes within the peptide binding pocket as well.
Thus, 1 ns MD simulations were conducted and later analyzed to
observe the changes in the RMSD of one of the ‘‘walls’’ that form
the peptide-binding pocket (helix 50–86.B) and the width of the
binding pocket via the monitoring of five selected distances
between the CA atoms of the residues that form this pocket
(Figure 4). The distance and RMSD fluctuations were analyzed
for the last 0.4 ns.
1. RMSD analysis. Because the initial conformation of HLA-
DP2 is the same for all cases (before the energy minimization
steps), it allowed us to monitor how it will change over a period of
time while binding different types of peptides and/or the Be ion.
Here, we are focusing on the changes associated with helix 50–
86.B (residues 50–86 of chain B), which forms one of the walls of
the binding pocket and is expected to play an important role in the
peptide and Be binding by HLA-DP2 and is expected to undergo
conformational changes which are different from the changes
observed for ‘‘natural’’ peptides in the absence of the Be ion.
In order to have a reference to compare with, the initial
simulations were done on the unbound HLA-DP2, on HLA-DP2
with natural peptide, and on HLA-DP2 with the bound Be ion
(Figure 6.A). One can see that in the unbound HLA-DP2, the
helix 50–86.B undergoes some conformational fluctuations and
reaches saturation at about 1.8 A˚. The same simulations that were
performed with ‘‘natural’’ peptides result in larger fluctuations,
reaching RMSD saturation at about 2.0 A˚. The simulations done
on HLA-DP2 with the bound Be indicate that Be increases the
magnitude of the fluctuations (60.1 A˚), but the saturation RMSD
is almost identical to the HLA-DP2 without Be. Based on these
results, it can be speculated that the binding of ‘‘natural’’ peptides
to the HLA-DP2 protein causes the helix 50–86.B to deviate
further from its crystallographic position and thus to open the
peptide binding side. These changes can be recognized by specific
TC receptors and trigger the ‘‘normal’’ cascade of signals.
Figure 6.B shows the RMSD without the Be ion present. It can
be seen that ‘‘natural’’ and ‘‘DR’’ peptide binding causes almost
the same RMSD on the HLA-DP2 complex, while the binding of
‘‘strong’’ and ‘‘weak’’ peptides in absence of Be causes a much
Figure 6. Change in RMSD of one of the walls of the peptide-binding pocket of HLA-DP2 during MD simulations in presence of
peptides and/or the Be ion.
doi:10.1371/journal.pone.0111604.g006
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larger RMSD of helix 50–86.B. The direction of the change, the
increase in the RMSD upon the binding of the peptides, is the
same as for binding ‘‘natural’’ peptides to HLA-DP2, and perhaps
will initiate the same immune cascade.
The simulations performed with all the sets of peptides (‘‘DR’’,
‘‘natural’’, ‘‘strong’’, and ‘‘weak’’) with the Be ion in the scenario
‘‘(Be+peptide)Rprotein’’ indicate that there is practically no
difference between the RMSD of the complexes (Figure 6.C).
This is similar to the RMSD induced by the Be ion alone and is in
agreement with the binding free energy calculations (Figure 5).
Indeed, all peptides within scenario ‘‘(Be+peptide)Rprotein’’ were
calculated to bind much more weakly than ‘‘normal’’ peptides in
the absence of the Be ion. This is the reason why the RMSD
fluctuations are very similar for all of the peptides to the RMSD of
Be-HLA-DP2, simply because the type of peptide does not matter.
If the same procedure is applied to the structures built under the
scenario ‘‘peptideR(Be+protein)’’, the effect is opposite (Fig-
ure 6.D). The binding of all peptides onto Be-HLA-DP2 complex
reduces the RMSD associated with helix 50–86.B. This response is
just opposite to the increase of RMSD of helix 50–86.B upon
binding of ‘‘natural’’ peptides in absence of the Be ion. The most
striking observation is that, in presence of the Be ion, peptides
from the ‘‘strong’’, ‘‘weak’’, and ‘‘DR’’ sets induce practically the
same conformational changes in helix 50–86.B: reduce both the
level of saturation and fluctuations compared to HLA-DP2 bound
to the ‘‘natural’’ peptides. The same is valid for ‘‘natural’’ peptides
to lesser extent. It can be viewed as the binding is rigidifying the
pocket. Since this change is completely opposite to the change
induced by the binding of ‘natural’’ peptides in the absence of Be,
it can be speculated that it might trigger a different signaling
cascade.
2. Analyzing the changes in the width of peptide-binding
pocket. To analyze the change in the size of peptide-binding
pocket upon the binding of the Be ion and peptides in the four
different sets, we monitored the change in the distances between
five selected positions within the helices that form the ‘‘walls’’ of
the pocket (see Figure 4). The results are shown in Figure 6 where
the position between CA atoms for each of the 5 pairs of residues
(see Figure 4, Table 1) averaged for the last 0.4 ns of MD
simulations within the corresponding set are plotted. To demon-
strate the distance fluctuations, we also included two standard
deviations of the average data as error bars on the graphs.
As in the previous paragraph, we begin the modeling with
simulations of peptide-free HLA-DP2, along with HLA-DP2
loaded with a ‘‘natural’’ peptide and with a Be ion. The results are
shown in Figure 7.A. It can be seen that in the case of free HLA-
DP2, the distance between the helices forming the gate of the
binding pocket fluctuates at each positions by about 4 A˚. Adding
the Be ion narrows the gate at positions D3–D5, while the
fluctuations remain almost the same as in the free HLA-DP2.
However, when the ‘‘natural’’ peptides are simulated with HLA-
DP2, the trend is the opposite: opening the pocket at positions D3–
D5 while reducing the fluctuations. Combined with the observa-
tions made in the previous section, these results indicate that the
binding of natural peptides to HLA-DP2 makes the binding pocket
wider while rigidifying it.
Figure 7.B shows the results for the four sets of peptides in the
absence of the Be ion. The calculated distances between the helices
forming the gate of the binding pocket are almost identical for
‘‘natural’’, ‘‘strong’’, and ‘‘weak’’ peptide sets. At first, this may be
considered as a contradiction of the observation made about the
RMSD of helix 50–86.B in the previous section. However, the
analysis of the other helix forming the gate indicates that the
Figure 7. Average distances between the CA atoms of residues forming peptide-binding pocket. Error bar illustrated as 6 two values of
standard deviation.
doi:10.1371/journal.pone.0111604.g007
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‘‘strong’’ and ‘‘weak’’ peptides in the absence of Be only deform
the pocket without changing its width. This indicates that the
presence of the Be ion may be an important factor for regulating
the conformational changes of the gate of the peptide binding
pocket.
The simulations of the complexes with HLA-DP2 loaded with
the four sets of peptides with the Be ion using structures delivered
via the ‘‘(Be+peptide)Rprotein’’ scenario are shown in Figure 7.C.
For comparison, the figure also shows the results for the HLA-DP2
with the ‘‘natural’’ peptides without Be. The data shows that there
is no difference in the size of the pocket between each of the sets of
peptides with the Be ion and the ‘‘natural’’ peptide without the
ion. The same similarities were shown previously while analyzing
the binding affinity (Figure 5.B) and the conformational changes of
helix 50–86.B (Figure 6.C).
The same calculations for the ‘‘peptideR(Be+protein)’’ scenario
(Fig 7.D) show that all sets of peptides bound to the HLA-DP2
cause the same conformational changes. This change is distinctly
smaller at the distance D3 as compared to HLA-DP2 loaded with
‘‘natural’’ peptides. In contrast, the length at distance markers D4
and D5 is slightly longer in comparison with the HLA-DP2 protein
in complex with the ‘‘natural’’ peptides. This is a distinctive
signature of the binding effects caused by binding of each of the
peptides onto HLA-DP2 already loaded with the Be ion. These
conformational changes are significantly different from the
conformational changes induced by the binding of ‘‘natural’’
peptides in the absence of the Be ion and perhaps will trigger a
different signaling cascade.
pKa calculation of ionizable residues due to small
peptides and/or Be ion binding to HLA-DP2
Binding frequently causes ionization changes, typically referred
to as proton uptake/release [44,45] and thus affects the
electrostatic component of the binding free energy [46]. To
investigate the effects of small peptides and the Be ion binding to
HLA-DP2 on the ionization states of titratable groups, we carried
out a pKa calculation using the MCCE program [41,42,43]. The
pKa’s of all ionizable residues of HLA-DP2 were calculated, and
the protonation changes caused by the peptide binding, especially
for the residues within the pocket, were analyzed. As described in
the methods section, 120 structures were subjected to the pKa
calculations. 40 of them were the HLA-DP2 bound with a peptide
in the absence of the Be ion and 40 of them were the protein-Be
complex bound to a small peptide and the rest were the protein
bound to the Be-peptide complex. They were also divided into 4
groups by the peptide categories: ‘‘DR’’, ‘‘natural’’, ‘‘strong’’, and
‘‘weak’’. Also, for each group, we obtained the average pKa values
of 10 structures along with the standard error and the calculated
pKa shift of them from the native HLA-DP2 protein (PDB ID:
3LZM) (see Figure 8).
We found two acidic residues, bGlu26 and bGlu69, always
experience a large pKa change that is caused by the peptide or Be
ion binding, although several other ionizable residues also showed
slight pKa shifts. Figure 8 shows the pKa shifts for bGlu26 (blue
bar) and bGlu69 (red bar) as HLA-DP2 binds four different types
of peptides in presence/absence of Be ion. The pKa values for
bGlu26 and bGlu69 on free HLA-DP2 are 6.2 and 6.8
respectively, i.e. they are almost neutral at pH = 7. We found that
in the absence of the Be ion, the pKa shift that was caused by the
binding of most of the types of peptides is less than 2.0 for bGlu26
and bGlu69 although the pKa shift for bGlu26 is about 3.5 for the
‘‘natural’’ and ‘‘DR’’ peptides. However, when the Be ion
participates in the binding, both pKa shifts increase significantly
and this results in deprotonation (both glutamic acids become fully
charged). Especially when the Be ion binds with HLA-DP2 first
and then the complex binds to the peptide, most of the pKa’s were
lowered more than 5.0, which indicates that the glutamic acids are
Figure 8. The pKa shift of two ionizable residues bGlu26 and
bGlu69 on (A) HLA-DP2 binds to peptides (Four types as
‘‘natural’’, ‘‘strong’’, ‘‘weak’’ and ‘‘DR’’, the same to the
followings) (B) peptides bind to the complex (Be+protein) (C)
(Be+peptides) complex binds to HLA-DP2 protein from pKa of
native unbond protein. The pKa value was calculated as the average
of 10 structures for each type of peptides.
doi:10.1371/journal.pone.0111604.g008
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fully deprotonated due to the Be ion. This is another observation
in favor of the hypothesis that the Be ion is crucial for the HLA-
DP2 response to the binding and the nature of the binding peptide
is a secondary factor. However, since the binding affinity strongly
differs among peptides, it is expected that ‘‘strong’’ peptides will
dominate.
Conclusions
Three questions were addressed in this study: (a) Where does the
Be ion bind?; (b) What is the sequence of the events for forming the
Be-HLA-DP2-peptide complex?; and (c) What is the specific
‘‘signature’’ of the effects induced by CBD-causing peptides and
Be?
The putative Be position was predicted by the BION server [30]
and it was found to be in the previously suggested acidic pocket
composed of three acidic residues, Glu26, Glu68 and Glu69
[20,23,26]. The predicted Be position was tested in MD
stimulations both with and without peptides and it was observed
that the Be ion stays within the pocket and does not drift away
within 1 ns of simulations. As the manuscript was under review,
the Be position was experimentally determined [1] and our
predicted Be position was in close proximity to the experimental
one (,3.2 A˚).
Our calculations show that for the scenario ‘‘(Be+peptide)R
protein’’ the conformational changes of the HLA-DP2 protein
induced by the peptides with the attached Be ion are identical to
those caused by ‘‘natural’’ peptides alone. This indicates that if this
scenario occurs in CBD development, then the common TC
receptors should recognize the complex and exert the ‘‘normal’’
immune response. However, the possibility of this scenario is
negligibly small because of a) the decreased binding affinity
between (Be+pepide) and protein and b) small peptides are very
flexible in the free state (unbound state) and holding the Be ion is
quite unlikely. In addition, since the binding energies for all four
sets of peptides in the scenario ‘‘(Be+peptide)Rprotein were much
worse when compared with the ‘‘peptideR(Be+protein)’’ scenario,
it was concluded that the ‘‘peptideR(Be+protein)’’ scenario is
more likely to occur in CBD.
Comparing the calculated effects across the four sets of peptides,
it can be suggested that the specific ‘‘signature’’ of CBD is
complex. The key player is the Be ion, which, when binds to the
acidic pocket of HLA-DP2, changes the conformational properties
of the peptide binding pocket. The peptide affinity is unaffected by
the Be presence, but once the peptides bind to the pocket pre-
loaded with the Be ion, they all induce similar conformational and
ionization changes. These changes are distinctively different from
the changes caused by the binding of ‘‘natural’’ peptides to the
HLA-DP2 in absence of Be and, thus, are expected to trigger a
completely different cascade of immune reactions which then leads
to CBD. This conclusion is supported by the experimental results
suggesting that in patients with CBD, the Be-specific CD4+T cells
(Vb5+CD4+T cell [47]) are responsible for the complex recogni-
tion and immune response propagation [48,49,50]. Furthermore,
recent experimental work suggests that Be-specific T cells
recognize the peptide-Be-HLA-DP2 complex via an unconven-
tional docking topology [51], which in our work is referred to as a
different conformational change of HLA-DP2 in CBD as
compared with the normal immune response. Thus, we hypoth-
esize that the peptide binding to the Be doped HLA-DP2 causes
CBD development as recently confirmed experimentally [1].
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